In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids. Max and Eric discuss Cannabinol (CBN), the minor cannabinoid at the heart of InMed’s programs, why the company chose it and the advantages it may have over cannabiodiol (CBD) and tetrahydrocannabinol (THC).

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step
Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,